Free Trial
NYSE:NKGN

NKGen Biotech 4/16/2024 Earnings Report

NKGen Biotech logo
$0.14 +0.00 (+2.34%)
As of 01:32 PM Eastern

NKGen Biotech EPS Results

Actual EPS
-$1.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NKGen Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NKGen Biotech Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NKGen Biotech Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
NKGen Biotech presents data from Phase 1/2a trial of troculeucel
See More NKGen Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NKGen Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NKGen Biotech and other key companies, straight to your email.

About NKGen Biotech

NKGen Biotech (NYSE:NKGN) operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

View NKGen Biotech Profile

More Earnings Resources from MarketBeat